The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Prediction and Prevention of Recurrent Preeclampsia
Abstract
Women with a history of previous preeclampsia are at increased risk of preeclampsia and other adverse pregnancy outcomes in subsequent pregnancies. The magnitude of this risk is dependent on gestational age at time of disease onset, severity of disease, and presence or absence of preexisting medical disorders. The objective in the management of these patients is to reduce risk factors by optimizing maternal health before conception and to detect obstetric complications as early as possible. This objective can be achieved by formulating a rational approach that includes preconception evaluation and counseling, early antenatal care, frequent monitoring of maternal and fetal well-being, and timely delivery. First-trimester ultrasound examination is essential for accurate dating and establishing fetal number. Laboratory studies are obtained to assess the function of different organ systems that are likely to be affected by preeclampsia and to establish a baseline for future assessment. Recent studies have confirmed that there is no single biomarker that can be clinically useful for the prediction of recurrent preeclampsia. Combinations of biomarkers and biophysical parameters appear promising, but more data are needed to confirm their use in clinical practice. Supplementation with fish oil, calcium, or vitamin C and E and the use of antihypertensives have been shown to be ineffective in the prevention of recurrent preeclampsia and are not recommended. Supplementation with low-dose aspirin may be offered on an individualized basis. Because women with previous preeclampsia are at increased risk for adverse pregnancy outcomes (preterm delivery, fetal growth restriction, abruptio placentae, and fetal death) in subsequent pregnancies, we recommend more frequent monitoring for signs and symptoms of severe hypertension or preeclampsia than that recommended for normal pregnancy. This monitoring may include more frequent prenatal visits, home blood pressure monitoring, or nursing contacts. For patients with a prior pregnancy complicated by preeclampsia with fetal growth restriction, we recommend serial ultrasound evaluation of fetal growth and amniotic fluid volume. The development of severe gestational hypertension, fetal growth restriction, or recurrent preeclampsia requires maternal hospitalization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720
Self-citation(2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.107928 · Cited by 3,270
Circulating angiogenic factors and the risk of preeclampsia*
(2004) · Obstetrics & Gynecology · doi:10.1097/00006250-200405000-00028 · Cited by 2,615
Sibai, B., Dekker, G., & Kupferminc, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17987-2 · Cited by 1,814
Self-citationSoluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
Levine, R. J., Lam, C., Qian, C., Yu, K. F., Maynard, S. E., Sachs, B. P., Sibai, B. M., Epstein, F. H., Romero, R., Thadhani, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055352 · Cited by 1,802
Self-citationSoluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
(2006) · New England Journal of Medicine · doi:10.1056/nejmx060063 · Cited by 1,235
Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data
Askie, L. M., Duley, L., Henderson-Smart, D. J., & Stewart, L. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60712-0 · Cited by 1,020
Sibai, B. M. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000126245.35811.2a · Cited by 801
Self-citationChappell, L. C., Seed, P. T., Briley, A. L., Kelly, F. J., Lee, R., Hunt, B. J., Parmar, K., Bewley, S. J., Shennan, A. H., Steer, P. J., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)80010-5 · Cited by 786
Evers, I. M., de Valk, H. W., & Visser, G. H. A. (2004) · BMJ · doi:10.1136/bmj.38043.583160.ee · Cited by 775
Cited by
Steegers, E. A., von Dadelszen, P., Duvekot, J. J., & Pijnenborg, R. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60279-6 · Cited by 2,850
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Young, B. C., Levine, R. J., & Karumanchi, S. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102149 · Cited by 719
Pre-eclampsia: pathophysiology, diagnosis, and management
Ayoubi (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s20181 · Cited by 546
Obesity, insulin resistance, and pregnancy outcome
Catalano, P. M. (2010) · Reproduction · doi:10.1530/rep-10-0088 · Cited by 447
Metadata
- Authors
- Barton, J. R., & Sibai, B. M.
- Venue
- Obstetrics & Gynecology
- Published
- 2008-08
- Volume
- 112
- Issue
- 2
- Pages
- 359-372
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2007801514
- Cited by
- 309
- References
- 90
- FWCI
- 27.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction and Prevention of Recurrent Preeclampsia. https://app.cochat.ai/papers/10.1097/aog.0b013e3181801d56
- The paper
- Barton, J. R., & Sibai, B. M. (2008). Prediction and Prevention of Recurrent Preeclampsia. Obstetrics & Gynecology. https://doi.org/10.1097/aog.0b013e3181801d56
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.